Cargando…
Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes
BACKGROUND: Nonmedical formulary switches (NMFS) routinely occur in managed health care plans and involve changing preferred medications for reasons outside of clinical considerations. The cost implications of NMFS are infrequently published and the clinical outcomes rarely assessed. OBJECTIVE: To a...
Autores principales: | Kheloussi, Steven, Johns, Alicia, Parente, Vincenzo, McLay, William, Gionfriddo, Michael R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390945/ https://www.ncbi.nlm.nih.gov/pubmed/34185559 http://dx.doi.org/10.18553/jmcp.2021.27.7.846 |
Ejemplares similares
-
Nonmedical switching of anticoagulants: The patient impact when formulary exclusions limit drug choice
por: Waldron, Beth
Publicado: (2022) -
Employer-Paid Nonmedical Costs for Patients With Diabetes and End-Stage Renal Disease
por: Kamal-Bahl, Sachin J, et al.
Publicado: (2006) -
Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors
por: Farr, Amanda M., et al.
Publicado: (2016) -
Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023) -
DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)